Back to results
US 11,530,186 B2Granted
Inhibitors for the β-catenin / T-cell factor protein-protein interaction
AssigneeH. Lee Moffitt Cancer Center and Research Center Institute, Inc.
InventorHaitao Ji
Life of this patent
Estimating the term…
Abstract
Disclosed are inhibitors for the β-catenin/T-cell factor interaction. The inhibitors are selective for β-catenin/T-cell factor over β-catenin/cadherin and β-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
Claims27
A compound having Formula I:
- wherein
- Cy1 is H or substituted or unsubstituted, mono or bicyclic aryl, heteroaryl, cycloalkyl, or cycloheteroalkyl;
- L1 is (CH2)2-4, CH2NHC(O), C(O)NHCH2, NHC(O)CH2, CH2C(O)NH, NHC(O), C(O)NH, CH2C(O)NH, NHC(O)CH2, C(O)NHCH2, CH2NHC(O), C(O)NHO, ONHC(O), C(O)NHOCH2, CH2ONHC(O), C(O)NHCH2CH2O, OCH2CH2NHC(O), C(O)NHCH2CH(OH)CH(OH), CH2C(O)O, OC(O)CH2, C(O)OCH2, CH2OC(O), C(O)O, OC(O), CH2C(O), C(O)CH2, CH2CH2C(O), C(O)CH2CH2, NH2, or O;
- Ar2 is substituted or unsubstituted, mono or bicyclic aryl, heteroaryl, or cycloheteroalkyl;
- L2 is (CH2)2-4;
- Ar3 is substituted or unsubstituted, mono or bicyclic heteroaryl;
- L3 is a bond, C≡C, or (CH2)1-4;
- and
- R4 is C(O)OC1-6 alkyl, tetrazole, or CN;
- wherein when substituted, the substituent is one or more of halo, C1-6 alkyl, C1-6 haloalky, C1-6 alkoxyl, C1-6 haloalkoxyl, or amino,
- or a pharmaceutically acceptable salt thereof.
8 more elements
Dependencies are inferred from the claim text.